Titan Pharmaceuticals, Inc. (de) TTNP

NAS: TTNP | ISIN: US8883145075 30/05/2024

6,510 USD (+2,20%)

(+2,20%) 30/05/2024

Toon enkel gratis nieuws

16 augustus 2022 · Titan Pharmaceuticals Announces Board Expansion and Management Changes · Persbericht

5 juli 2022 · Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant · Persbericht

2 februari 2022 · Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market · Persbericht

8 november 2021 · Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021 · Persbericht

5 november 2021 · Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021 · Persbericht

25 oktober 2021 · Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries · Persbericht

12 oktober 2021 · Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement · Persbericht

23 juni 2021 · Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus · Persbericht

31 maart 2021 · Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K · Persbericht

1 februari 2021 · Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program · Persbericht

15 januari 2021 · Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe